116 filings
Page 5 of 6
8-K
871emyhk1eg1bqz
10 Oct 18
Regulation FD Disclosure
5:25pm
8-K
fnk972q9
24 Sep 18
Entry into a Material Definitive Agreement
5:27pm
8-K
k0ofz0mt0 a8
21 Sep 18
Crispr Therapeutics Announces Proposed Public Offering of Common Shares
4:16pm
8-K
xweatm7d
17 Sep 18
CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes
12:00am
8-K
75mew 9e317ll55w3k8g
11 Sep 18
Other Events
12:00am
8-K
tvdhiz5gl3 o1fwr0
31 Aug 18
Entry into a Material Definitive Agreement
12:00am
8-K
wrq3wd69u6ov
7 Aug 18
Reports Second Quarter 2018 Financial Results
5:10pm
8-K
uau6s7k tz98yl1jli
1 Jun 18
Departure of Directors or Certain Officers
5:05pm
8-K
1xfmfv33
30 May 18
CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug
4:37pm
8-K
yph8a1237npxx3a721cg
8 May 18
Reports First Quarter 2018 Financial Results
7:43am
8-K
2z3m i3rq3da
8 Mar 18
Reports Fourth Quarter and Full Year 2017 Financial Results
12:00am
8-K
nixjvlbzbz7o2rsj9 f7
5 Jan 18
CRISPR Therapeutics Announces Proposed Public Offering of Common Shares
12:00am
8-K
g90lmded9biv
21 Dec 17
CRISPR Therapeutics Announces Appointment of Dr. Rodger Novak as Chairman of the Board
12:00am
8-K
wwkkcj6if3n1qxm
18 Dec 17
Vertex and CRISPR Therapeutics toCo-Develop andCo-Commercialize
12:00am
8-K
bfr5hfe
7 Dec 17
Other Events
12:00am
8-K
v3t2y7qb c87mn0j
13 Nov 17
CRISPR Therapeutics Announces Appointment of Michael Tomsicek as Chief Financial Officer
12:00am
8-K
o6b ayosdl22qoc
8 Nov 17
CRISPR Therapeutics Announces Third Quarter 2017 Financial Results
12:00am
8-K
fo6usbzni2gz4pip cfs
7 Nov 17
Other Events
12:00am
8-K
crh252d
2 Oct 17
CRISPR Therapeutics Announces Promotion of
12:00am
8-K
3834enicrs
10 Aug 17
CRISPR Therapeutics Announces Second Quarter 2017 Financial Results
12:00am